The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1690-1696

  Hernberg, M ^a   Muhonen, T ^a   Turunen, J P ^a   Hahka Kemppinen, M ^a   Pyrhonen S ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CD4 ANTIGEN; CD8 ANTIGEN; DACARBAZINE; FINNFERON ALPHA; LOMUSTINE; OKT 4; OKT 8; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029862680     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1690     Document Type: Article

References (33)

1. Kirkwood JM: Biology of melanoma relevant to biological therapy with interferons, in DeVita JVT, Hellman S, Rosenberg S (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, 1995, pp 388-394
2. Bernengo MG, Lisa F, Puiatti P, et al: T-cell subsets in melanoma patients evaluated by anti-T-cell monoclonal antibodies. Thymus 5:223-233, 1983
3. Bernengo MG, Lisa F, Meregalli M, et al: The prognostic value of T-lymphocyte levels in malignant melanoma. A 5-year follow-up. Cancer 52:1841-1848, 1983
4. Garbe C, Krasagakis K: Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 100:239S-244S, 1993 (suppl)
5. Bash JA, Teitelbaum D, Sreevalsan T, et al: Immunomodulatory activities of human leukocyte interferon in advanced cancer patients. J Biol Response Modif 2:57-65, 1983
6. Lucero MA, Magdelenat H, Fridman WH, et al: Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients. Eur J Cancer Clin Oncol 18:243-251, 1982
7. Mitchell MS, Birnbaum MM, Davis JM: Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma. J Clin Invest 59:1017-1026, 1977
8. Pyrhönen S, Hahka-Kemppinen M, Muhonen T: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10:1919-1926, 1992
9. Punt CJA, Jansen RLH, Vreugdenhil A, et al: Combination chemotherapy together with interferon-alpha (IFN) in metastatic melanoma (MM), a multicenter phase II study. Proc Am Soc Clin Oncol 14:411, 1995 (abstr 1301)
10. Nathan FE, Sato T, Berd D, et al: BOLD + interferon: Effective systemic therapy for metastatic uveal melanoma. Proc Am Soc Clin Oncol 14:410, 1995 (abstr 1297)
11. Muhonen T, Hahka-Kemppinen M, Pakkala S, et al: Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma. J Immunother 15:67-73, 1994
12. Knapp W: Leukocyte typing IV. IVth International Workshop and Conference on Human Leukocyte Differentiation Antigens, Vienna, Austria, 1989
13. Jackson AL, Warner NL: Preparation, staining and analysis by flow cytometry of peripheral blood leukocytes, in Rose NR, Friedman H, Fahey JL (eds): Manual of Clinical Immunology. Washington, DC, American Society of Microbiology, 1986, pp 226-235
14. Simony J, Rossi JF, Shishehian B, et al: Characterization of proliferative cells in malignant melanomas and their inflammatory infiltrates. Cancer Detect Prev 15:183-187, 1991
15. Tefany FJ, Barnetson RS, Halliday GM, et al: Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 97:197-202, 1991
16. Li Y, McGowan P, Hellstrom I, et al: Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421-428, 1994
17. Karavodin LM, Golub SH: Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment. Nat Immunol Cell Growth Regul 3:193-202, 1983
18. Soubrane C, Mouawad R, Ichen M, et al: Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol 95:232-236, 1994
19. Hersey P, Hasic E, MacDonald M, et al: Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma. Br J Cancer 51:815-826, 1985
20. Hersey P, Coates A, Rallings M, et al: Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma. J Biol Response Mod 5:236-249, 1986
21. Kirkwood JM, Ernstoff MS, Trautman T, et al: In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma. J Clin Oncol 8:1070-1082, 1990
22. Grups JW, Frohmuller HG: Influence of cyclic interferon gamma on lymphocytes and their subpopulations in patients with renal carcinoma. Urology 35:111-113, 1990
23. Aulitzky WE, Aulitzky W, Gastl G, et al: Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer. J Interferon Res 9:425-433, 1989
24. Kirkwood JM, Ernstoff MS: Potential applications of interferons in oncology. Semin Oncol 13:48-56, 1986
25. Knop J: Immunologic effects of interferon. J Invest Dermatol 95:72S-74S, 1990
26. Bernengo MG, Lisa F, Meregalli M, et al: Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma. Int J Tissue React 6:505-511, 1984
27. + suppressor-inducer T-cells. Cancer Res 48:1671-1675, 1988
28. Bast RJ, Reinherz EL, Maver C, et al: Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 28:101-114, 1983
29. Hoon DS, Foshag LJ, Nizze AS, et al: Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res 50:5358-5364, 1990
30. Mosmann TR: Cytokine secretion patterns and cross-regulation of T cell subsets. Immunol Res 10:183-188, 1991
31. Romagnani S: Human TH1 and TH2 subsets: Regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 98:279-285, 1992
32. Fitch FW, McKisic MD, Lancki DW, et al: Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol 11:29-48, 1993
33. Parronchi P, De CM, Manetti R, et al: IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 149:2977-2983, 1992